Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa University, Addis Ababa, Ethiopia.
J Infect Dis. 2024 Aug 16;230(2):e241-e246. doi: 10.1093/infdis/jiad591.
Cure rates for pulmonary disease caused by the Mycobacterium avium complex (MAC) are poor. While β-lactam are front line antibiotics against Mycobacterium abscessus pulmonary disease, they have not been used or recommended to treat MAC lung infections. Through a comprehensive screen of oral β-lactams, we have discovered that selected pairs combining either a penem/carbapenem or penicillin with a cephalosporin are strongly bactericidal at clinically achieved concentrations. These dual β-lactam combinations include tebipenem and sulopenem, both in phase 3, and Food and Drug Administration-approved amoxicillin and cefuroxime. They could therefore immediately enter clinical trials or clinical practice.
分枝杆菌复合群（MAC）引起的肺部疾病的治愈率很低。虽然β-内酰胺类药物是治疗脓肿分枝杆菌肺部疾病的一线抗生素，但它们尚未被用于或推荐用于治疗 MAC 肺部感染。通过对口服β-内酰胺类药物进行全面筛选，我们发现，选择将碳青霉烯类/青霉素类与头孢菌素类联合使用的组合，在临床达到的浓度下具有很强的杀菌作用。这些双联β-内酰胺类组合包括处于 3 期临床试验阶段的替比培南和 sulopenem，以及经美国食品和药物管理局批准的阿莫西林和头孢呋辛。因此，它们可以立即进入临床试验或临床实践。
